Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation.

Cruz LJ, Tacken PJ, van der Schoot JMS, Rueda F, Torensma R, Figdor CG.

Molecules. 2019 May 12;24(9). pii: E1825. doi: 10.3390/molecules24091825.

2.

The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage.

Torensma R.

Cancers (Basel). 2018 Nov 12;10(11). pii: E431. doi: 10.3390/cancers10110431.

3.

Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG.

Wefers C, Schreibelt G, Massuger LFAG, de Vries IJM, Torensma R.

Front Immunol. 2018 Jun 19;9:1412. doi: 10.3389/fimmu.2018.01412. eCollection 2018.

4.

Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System.

Wefers C, Duiveman-de Boer T, Zusterzeel PLM, Massuger LFAG, Fuchs D, Torensma R, Wheelock CE, de Vries IJM.

Int J Mol Sci. 2018 Jan 17;19(1). pii: E273. doi: 10.3390/ijms19010273.

5.

Umbilical cord blood CD34+ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice.

Hoogstad-van Evert JS, Cany J, van den Brand D, Oudenampsen M, Brock R, Torensma R, Bekkers RL, Jansen JH, Massuger LF, Dolstra H.

Oncoimmunology. 2017 May 11;6(8):e1320630. doi: 10.1080/2162402X.2017.1320630. eCollection 2017.

6.

Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity.

Cruz LJ, Tacken PJ, Eich C, Rueda F, Torensma R, Figdor CG.

Nanomedicine (Lond). 2017 Mar;12(5):491-510. doi: 10.2217/nnm-2016-0295. Epub 2017 Feb 9.

PMID:
28181470
7.

Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines.

Bakdash G, Buschow SI, Gorris MA, Halilovic A, Hato SV, Sköld AE, Schreibelt G, Sittig SP, Torensma R, Duiveman-de Boer T, Schröder C, Smits EL, Figdor CG, de Vries IJ.

Cancer Res. 2016 Aug 1;76(15):4332-46. doi: 10.1158/0008-5472.CAN-15-1695. Epub 2016 Jun 20.

8.

The European antibody network's practical guide to finding and validating suitable antibodies for research.

Roncador G, Engel P, Maestre L, Anderson AP, Cordell JL, Cragg MS, Šerbec VČ, Jones M, Lisnic VJ, Kremer L, Li D, Koch-Nolte F, Pascual N, Rodríguez-Barbosa JI, Torensma R, Turley H, Pulford K, Banham AH.

MAbs. 2016;8(1):27-36. doi: 10.1080/19420862.2015.1100787. Epub 2015 Sep 29.

9.

Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue.

Prinsen H, van Laarhoven HW, Pots JM, Duiveman-de Boer T, Mulder SF, van Herpen CM, Jacobs JF, Leer JW, Bleijenberg G, Stelma FF, Torensma R, de Vries IJ.

Hum Vaccin Immunother. 2015;11(7):1634-40. doi: 10.1080/21645515.2015.1040207.

10.

Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.

Wefers C, Lambert LJ, Torensma R, Hato SV.

Gynecol Oncol. 2015 May;137(2):335-42. doi: 10.1016/j.ygyno.2015.02.019. Epub 2015 Feb 26. Review.

PMID:
25727651
11.

Lithium inhibits palatal fusion and osteogenic differentiation in palatal shelves in vitro.

Meng L, Wang X, Torensma R, Von den Hoff JW, Bian Z.

Arch Oral Biol. 2015 Mar;60(3):501-7. doi: 10.1016/j.archoralbio.2014.12.011. Epub 2014 Dec 18.

PMID:
25555252
12.

Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.

Vasaturo A, Verdoes M, de Vries J, Torensma R, Figdor CG.

Immunobiology. 2015 Feb;220(2):243-8. doi: 10.1016/j.imbio.2014.11.007. Epub 2014 Nov 15. Review.

PMID:
25466585
13.

Cord blood mesenchymal stem cells suppress DC-T Cell proliferation via prostaglandin B2.

van den Berk LC, Jansen BJ, Snowden S, Siebers-Vermeulen KG, Gilissen C, Kögler G, Figdor CG, Wheelock CE, Torensma R.

Stem Cells Dev. 2014 Jul 15;23(14):1582-93. doi: 10.1089/scd.2013.0433. Epub 2014 Apr 23.

14.

Aiming to immune elimination of ovarian cancer stem cells.

Di J, Duiveman-de Boer T, Figdor CG, Torensma R.

World J Stem Cells. 2013 Oct 26;5(4):149-62. doi: 10.4252/wjsc.v5.i4.149. Review.

15.

Wnt16 is involved in intramembranous ossification and suppresses osteoblast differentiation through the Wnt/β-catenin pathway.

Jiang Z, Von den Hoff JW, Torensma R, Meng L, Bian Z.

J Cell Physiol. 2014 Mar;229(3):384-92. doi: 10.1002/jcp.24460.

PMID:
24037946
16.

The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients.

Di J, Duiveman-de Boer T, Zusterzeel PL, Figdor CG, Massuger LF, Torensma R.

Cell Oncol (Dordr). 2013 Oct;36(5):363-74. doi: 10.1007/s13402-013-0142-8. Epub 2013 Aug 9.

PMID:
23928726
17.

Functional OCT4-specific CD4+ and CD8+ T cells in healthy controls and ovarian cancer patients.

Di J, Massuger LF, Duiveman-de Boer T, Zusterzeel PL, Figdor CG, Torensma R.

Oncoimmunology. 2013 May 1;2(5):e24271. Epub 2013 Apr 1.

18.

The multiple faces of prostaglandin E2 G-protein coupled receptor signaling during the dendritic cell life cycle.

De Keijzer S, Meddens MB, Torensma R, Cambi A.

Int J Mol Sci. 2013 Mar 25;14(4):6542-55. doi: 10.3390/ijms14046542. Review.

19.

Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome.

Prinsen H, de Vries IJ, Torensma R, Pots JM, Mulder SF, van Herpen CM, Elving LD, Bleijenberg G, Stelma FF, van Laarhoven HW.

BMC Immunol. 2012 Dec 17;13:71. doi: 10.1186/1471-2172-13-71.

20.

Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.

Cruz LJ, Rueda F, Tacken P, Albericio F, Torensma R, Figdor CG.

Nanomedicine (Lond). 2012 Oct;7(10):1591-610. doi: 10.2217/nnm.12.131. Review.

PMID:
23148541

Supplemental Content

Loading ...
Support Center